Advertisement
Advertisement
U.S. markets close in 1 hour 48 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Exicure, Inc. (XCUR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1249+0.0034 (+2.80%)
As of 02:09PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close0.1215
Open0.1200
Bid0.1250 x 1400
Ask0.1254 x 1300
Day's Range0.1200 - 0.1319
52 Week Range0.0950 - 1.9800
Volume7,337,618
Avg. Volume13,432,077
Market Cap15.338M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-0.6190
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XCUR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exicure, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    20 hours agoMorningstar
View more
Advertisement
Advertisement